Lecture Summary - ASCO 2022 Phase 2 Study of Response-Guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Localized TNBC: Results From the NeoSTAR Trial

37 views
June 21, 2022
Comments 0
Login to view comments. Click here to Login